 Home > Active Ingredient News > Antitumor Therapy > BJU Int: Should patients with non-muscular invasive bladder cancer stop using fibrin clot inhibitors during BCG?

BJU Int: Should patients with non-muscular invasive bladder cancer stop using fibrin clot inhibitors during BCG?

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

soy cause cancer

ovarian cancer cells

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Intravesical BCG vaccine (BCG) is the main treatment for medium and high-risk non-muscular invasive bladder cancer (NMIBC)

Some meta-analyses have stated that BCG is superior to intravenous chemotherapy in terms of recurrence, and mainly when used as maintenance treatment.

Among patients using fibrin clot inhibitors (FCI), previous reports evaluating the clinical efficacy of intravenous BCG (BCG) therapy are conflicting, and are mainly based on the group of patients receiving only inducible BCG

Recently, researchers from the United States published an article in "BJU Int" to determine the impact of FCI on oncology results in a cohort of patients with non-muscular invasive bladder cancer (NMIBC) who received adequate BCG therapy

Determined the contemporary non-muscular invasive bladder cancer (NMIBC) patient cohort who received adequate BCG therapy, and the influence of FCI on oncology results determined the contemporary non-muscular invasive bladder cancer (NMIBC) patient cohort who received adequate BCG therapy , The impact of FCI on oncology results

Between 2000 and 2018, the researchers conducted a review approved by the Institutional Review Board on NMIBC patients who received adequate intravenous BCG therapy

It was found that 226 (43.

Progression-free survival under different drug use conditions

In summary, in a large contemporary cohort of patients receiving adequate intravenous BCG for non-muscular invasive bladder cancer, the use of fibrin clot inhibitors is not associated with adverse tumor outcomes

Receiving full intravenous BCG therapy of non-muscle invasive bladder cancer contemporary large cohort of patients, fibrin clot inhibitor of tumor adverse outcomes regardless of large full receiving intravenous BCG therapy of non-muscle invasive bladder cancer Contemporary In the patient cohort, the use of fibrin clot inhibitors is not associated with adverse tumor outcomes

Original source:

Niyati Lobo, Patrick J Hensley, Kelly K Bree et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.